MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

October 31, 2017

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) announced today it can now purchase generic hepatitis C medicines for as low as $1.40 per day, or $120 per 12-week treatment course, for two key medicines used to treat and cure this disease, sofosbuvir and daclatasvir. This dramatic price reduction—which will benefit patients in countries where MSF can supply generic versions—illustrates the importance of generic options, which could, if expanded, help countries provide treatment for millions of people and improve public health by preventing the spread of this disease.

June 27, 2017

A leaked draft of President Trump’s executive order on drug pricing reveals that the White House will perpetuate policies that have led to a broken biomedical research and development (R&D) system and raise drug prices around the world, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF).

May 25, 2017

Ahead of the G7 summit that’s starting tomorrow in Italy, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is urging participating countries to address high medicine prices and drug-resistant infections, which affect people everywhere. Today, across the G7, countries are struggling to pay for new medicines to treat life-threatening illnesses like hepatitis C.

March 27, 2017

First patent opposition MSF has filed in Europe aims to increase affordable access to hepatitis C drug sofosbuvir for millions

NEW YORK/ROME/GENEVA, MARCH 27, 2017—In an effort to increase access to affordable hepatitis C treatment, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) filed a patent challenge on the lifesaving hepatitis C drug sofosbuvir with the European Patent Office (EPO) today.

February 14, 2017

NEW YORK/NEW DELHI, FEBRUARY 14, 2017—Five new challenges against flawed patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral (DAA) medicines, including sofosbuvir, daclatasvir and velpatasvir, and increase access for millions of people.

September 14, 2016

New report exposes pharmaceutical industry failings and highlights new ways of researching and developing medicines that address public health needs.

May 26, 2016

New York/Ise-Shima/Geneva—As the leaders of the G7 countries gather in Ise-Shima, Japan over the next two days, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is urging them to make a bold commitment to prioritize a better global response to public health emergencies and to take action to encourage the research and development (R&D) and affordable pricing of critical medicines.

March 29, 2016

MSF urges Indian Prime Minister not to cave into pressure from EU to accept trade deal that could prevent millions of people from accessing lifesaving medicines

Pages

October 31, 2017

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) announced today it can now purchase generic hepatitis C medicines for as low as $1.40 per day, or $120 per 12-week treatment course, for two key medicines used to treat and cure this disease, sofosbuvir and daclatasvir. This dramatic price reduction—which will benefit patients in countries where MSF can supply generic versions—illustrates the importance of generic options, which could, if expanded, help countries provide treatment for millions of people and improve public health by preventing the spread of this disease.

June 27, 2017

A leaked draft of President Trump’s executive order on drug pricing reveals that the White House will perpetuate policies that have led to a broken biomedical research and development (R&D) system and raise drug prices around the world, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF).

May 25, 2017

Ahead of the G7 summit that’s starting tomorrow in Italy, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is urging participating countries to address high medicine prices and drug-resistant infections, which affect people everywhere. Today, across the G7, countries are struggling to pay for new medicines to treat life-threatening illnesses like hepatitis C.

March 27, 2017

First patent opposition MSF has filed in Europe aims to increase affordable access to hepatitis C drug sofosbuvir for millions

NEW YORK/ROME/GENEVA, MARCH 27, 2017—In an effort to increase access to affordable hepatitis C treatment, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) filed a patent challenge on the lifesaving hepatitis C drug sofosbuvir with the European Patent Office (EPO) today.

February 14, 2017

NEW YORK/NEW DELHI, FEBRUARY 14, 2017—Five new challenges against flawed patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral (DAA) medicines, including sofosbuvir, daclatasvir and velpatasvir, and increase access for millions of people.

September 14, 2016

New report exposes pharmaceutical industry failings and highlights new ways of researching and developing medicines that address public health needs.

May 26, 2016

New York/Ise-Shima/Geneva—As the leaders of the G7 countries gather in Ise-Shima, Japan over the next two days, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is urging them to make a bold commitment to prioritize a better global response to public health emergencies and to take action to encourage the research and development (R&D) and affordable pricing of critical medicines.

March 29, 2016

MSF urges Indian Prime Minister not to cave into pressure from EU to accept trade deal that could prevent millions of people from accessing lifesaving medicines

Pages